# A Study in Patients With Advanced Cancers

> **NCT05320588** · PHASE1,PHASE2 · RECRUITING · sponsor: **BiOneCure Therapeutics Inc.** · enrollment: 332 (estimated)

## Conditions studied

- Advanced Cancer
- Advanced Solid Tumor
- Cancer
- Oncology

## Interventions

- **DRUG:** BIO-106
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT05320588
- **Lead sponsor:** BiOneCure Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-03-25
- **Primary completion:** 2024-04
- **Final completion:** 2027-04
- **Target enrollment:** 332 (ESTIMATED)
- **Last updated:** 2022-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05320588

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05320588, "A Study in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05320588. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*